Sagimet Biosciences Surges Forward With Successful Acne Clinical Data and Capital Raise
Sagimet Biosciences Inc. (NASDAQ: SGMT ) reported 52-week data from a Phase 3 trial evaluating denifanstat for moderate to severe acne vulgaris. In January, the company shared topline data from the study. Concurrently, the clinical-stage biopharmaceutical firm priced an underwritten public offering expected to yield $1